Article
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Nature - 28 Feb 2008
Sakai Wataru, Swisher Elizabeth M, Karlan Beth Y, Agarwal Mukesh K, Higgins Jake, Friedman Cynthia, Villegas Emily, Jacquemont Céline, Farrugia Daniel J, Couch Fergus J, Urban Nicole, Taniguchi Toshiyasu
Abstract excerpt
Ovarian carcinomas with mutations in the tumour suppressor BRCA2 are particularly sensitive to platinum compounds. However, such carcinomas ultimately develop cisplatin resistance. The mechanism of that resistance is largely unknown. Here we show that acquired resistance to cisplatin can be mediated by secondary intragenic mutations in BRCA2 that restore the wild-type BRCA2 reading frame. First, in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.